semaglutide obstructive sleep apnea trial Diabetes & Weight Loss Drug Tirzepatide Now Approved for OSA (Obstructive Apnea) Obstructive sleep apnea — a

The TRIUMPH-4 Phase 3 data provides the most current safety information: Nausea: 38.1% (9 mg) to 43.2% (12 mg) versus 10.7% placebo Diarrhea: 34.7% (9 mg) to 33.1% (12 mg) versus 13.4% placebo Constipation: 21.8% (9 mg) to 25.0% (12 mg) versus 8.7% placebo Vomiting: 20.4% (9 mg) to 20.9% (12 mg) versus 0% placebo Decreased appetite: 19.0% (9 mg) to 18.2% (12 mg) versus 9.4% placebo The pattern is clear

Son efectivos para estreimiento agudo y pueden usarse de forma intermitente o como rescate

Como suplemento diettico, tomar un vial al da, preferiblemente antes del desayuno

The Svensson et al

Sau n i vo mu, ti thi im c th bn c th s dng vitamin A

( 1 ) Originally approved to treat type 2 diabetes, researchers began creating more targeted versions of GLP-1 medications after it was found that diabetes patients taking the medication often lost weight, sometimes without even intentionally trying